2020 journal article

Atenolol in cats with subclinical hypertrophic cardiomyopathy: a double-blind, placebo-controlled, randomized clinical trial of effect on quality of life, activity, and cardiac biomarkers

JOURNAL OF VETERINARY CARDIOLOGY, 30, 77–91.

By: A. Coleman n, T. DeFrancesco n, E. Griffiths n, B. Lascelles n, D. Kleisch n, C. Atkins n, B. Keene n

author keywords: Feline; Beta-btocker; Accelerometry
MeSH headings : Administration, Oral; Animals; Anti-Arrhythmia Agents / administration & dosage; Anti-Arrhythmia Agents / therapeutic use; Atenolol / administration & dosage; Atenolol / therapeutic use; Biomarkers / blood; Cardiomyopathy, Hypertrophic / drug therapy; Cardiomyopathy, Hypertrophic / veterinary; Cat Diseases / blood; Cat Diseases / drug therapy; Cats; Double-Blind Method; Female; Male; Quality of Life; Treatment Outcome
TL;DR: This study failed to identify an effect of subclinical HCM on owner-assessed QOL or activity or a treatment effect of atenolol on these variables at the dosage evaluated, and these findings do not support a treatment benefit of atanolol for the goal of symptom reduction in cats with sub clinical HCM. (via Semantic Scholar)
UN Sustainable Development Goals Color Wheel
UN Sustainable Development Goal Categories
Sources: Web Of Science, NC State University Libraries, ORCID
Added: September 21, 2020

Citation Index includes data from a number of different sources. If you have questions about the sources of data in the Citation Index or need a set of data which is free to re-distribute, please contact us.

Certain data included herein are derived from the Web of Science© and InCites© (2025) of Clarivate Analytics. All rights reserved. You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.